In a session called “Five Fixes For Healthcare” at the recent Forbes Healthcare Summit, concerns were raised about how innovative the biopharmaceutical industry really is. Dr. Laurie Glimcher, CEO of the Dana-Farber Cancer Institute, chided the industry saying that, when it comes to productivity, we “need to make a distinction between drugs that are transformative and drugs that are ‘me-too’.” Dr. George Yancopoulos, President and Chief Scientific Officer of Regeneron, was even more strident in his remarks, criticizing the industry’s 2016 new drug output noting that of the 22 FDA approvals only seven compounds were novel breakthroughs.
Image: Johnny Wolf George Yancopoulos, president and chief scientific officer of Regeneron, at the 2017 Forbes Healthcare Summit
